| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/1097-0142(195611/12)9:6<1211::AID-CNCR2820090624>3.0.CO;2-7 |
| P698 | PubMed publication ID | 13383455 |
| P2093 | author name string | HUEBNER RJ | |
| ROWE WP | |||
| THOMAS LB | |||
| SMITH RR | |||
| SCHATTEN WE | |||
| P2860 | cites work | Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture | Q33968768 |
| Pharyngoconjunctival fever; epidemiological studies of a recently recognized disease entity | Q41029118 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1211-1218 | |
| P577 | publication date | 1956-11-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Studies on the use of viruses in the treatment of carcinoma of the cervix | |
| P478 | volume | 9 |
| Q95808112 | 17. Histidine based pH-responsive polymeric micelle for tumor: Original research article: Polymeric micelle for tumor pH folate-mediated targeting, 2003 |
| Q45858715 | A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model |
| Q41895192 | Acute respiratory illness in volunteers following intramuscular administration of live adenovirus |
| Q37409025 | Adenoviral vector-based strategies for cancer therapy |
| Q43842247 | Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer |
| Q41628950 | Adenoviral vectors for gene transfer |
| Q37539305 | Adenovirus with DNA Packaging Gene Mutations Increased Virus Release |
| Q36132288 | Adenoviruses for treatment of cancer |
| Q35043106 | Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes |
| Q39575536 | Attenuated mumps virus therapy of carcinoma of the maxillary sinus |
| Q40655850 | Biopharmaceuticals and gene vectors opening new avenues in cancer immune therapy |
| Q34079568 | Bioreducible polymers for therapeutic gene delivery |
| Q91816717 | Cancer Treatment Goes Viral: Using Viral Proteins to Induce Tumour-Specific Cell Death |
| Q35081097 | Cancer gene therapy |
| Q37209758 | Cancer, stem cells, and oncolytic viruses |
| Q35142325 | Chapter One---Cancer terminator viruses and approaches for enhancing therapeutic outcomes |
| Q46894623 | Chimeric form of tumor necrosis factor-alpha has enhanced surface expression and antitumor activity |
| Q34225918 | Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? |
| Q36720873 | Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress |
| Q34361481 | Clinical trials of adenoviral-mediated suicide gene therapy of malignant gliomas |
| Q35610303 | Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses |
| Q34115068 | Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer. |
| Q93167440 | Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors |
| Q34625495 | Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment |
| Q35967313 | Conditionally replicating adenoviruses for cancer treatment. |
| Q45861487 | Conditionally replicating viruses in cancer therapy |
| Q34571833 | Conditionally replicative adenoviral vectors for cancer gene therapy |
| Q35842604 | Conditionally replicative adenovirus for gastrointestinal cancers |
| Q45868174 | Conditionally replicative adenoviruses for cancer therapy |
| Q33730705 | Current issues and future directions of oncolytic adenoviruses |
| Q34258563 | Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors |
| Q39491840 | Effects of capsid-modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer |
| Q33252754 | Efficient generation of double heterologous promoter controlled oncolytic adenovirus vectors by a single homologous recombination step in Escherichia coli |
| Q35624010 | Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials. |
| Q36594178 | Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers |
| Q39685569 | Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes. |
| Q34127138 | Experimental approaches for the treatment of malignant gliomas |
| Q35883639 | Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission |
| Q33908950 | Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus |
| Q34511278 | From molecular changes to customised therapy |
| Q35110573 | Gene Therapy for Pancreatic Cancer Targeting the Genomic Alterations of Tumor Suppressor Genes using Replication-selective Oncolytic Adenovirus |
| Q38854625 | Gene and virotherapy for hematological malignancies |
| Q33516121 | Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China |
| Q38297124 | Gene therapy and imaging in preclinical and clinical oncology: recent developments in therapy and theranostics |
| Q44676658 | Gene therapy in the clinics: shifting into the next gear |
| Q36922247 | Gene therapy of gynaecological diseases |
| Q26797520 | Going viral: a review of replication-selective oncolytic adenoviruses |
| Q34575505 | History of oncolytic viruses: genesis to genetic engineering |
| Q36184357 | Immunocompetent syngeneic cotton rat tumor models for the assessment of replication-competent oncolytic adenovirus |
| Q43653603 | Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy |
| Q46216400 | Inefficient killing of quiescent human epithelial cells by replicating adenoviruses: potential implications for their use as oncolytic agents |
| Q45869133 | Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer |
| Q90257528 | Intratumoral Immunotherapy-Update 2019 |
| Q37388577 | Measles virus for cancer therapy |
| Q38715077 | Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas |
| Q35223768 | Mining the adenovirus virome for oncolytics against multiple solid tumor types |
| Q39776556 | Mutual interference of adenovirus infection and myc expression |
| Q24680538 | ONCOLYTIC EFFECT OF POLIOMYELITIS VIRUS ON HUMAN EPIDERMOID CARCINOMA (HELA TUMOR) HETEROLOGOUSLY TRANSPLANTED TO GUINEA PIGS |
| Q35699072 | ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN. |
| Q37031925 | On the potential of oncolytic virotherapy for the treatment of canine cancers |
| Q26777406 | Oncolytic Replication of E1b-Deleted Adenoviruses |
| Q40051845 | Oncolytic Viral Therapy for Mesothelioma |
| Q58110086 | Oncolytic Viruses for Canine Cancer Treatment |
| Q34432804 | Oncolytic Viruses to Treat Ovarian Cancer Patients - a Review of Results From Clinical Trials |
| Q40064850 | Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer |
| Q55423899 | Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancer. |
| Q39125899 | Oncolytic adenoviruses: design, generation, and experimental procedures |
| Q45717272 | Oncolytic effect of Newcastle disease virus on Yoshida sarcoma (1). |
| Q35613495 | Oncolytic herpes viruses as a potential mechanism for cancer therapy. |
| Q39437344 | Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer |
| Q35852258 | Oncolytic viral therapies |
| Q37533665 | Oncolytic viral therapy of malignant glioma |
| Q34452020 | Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials |
| Q37818831 | Oncolytic virotherapy of gynecologic malignancies |
| Q26862461 | Oncolytic virotherapy using herpes simplex virus: how far have we come? |
| Q38924529 | Oncolytic virus therapy for cancer |
| Q26739714 | Oncolytic virus therapy: A new era of cancer treatment at dawn |
| Q33888224 | Oncolytic viruses |
| Q34234147 | Oncolytic viruses and cancer therapy |
| Q34329548 | Oncolytic viruses as therapeutic agents |
| Q36769180 | Oncolytic viruses in cancer therapy |
| Q38577450 | Oncolytic viruses: a new class of immunotherapy drugs |
| Q35610296 | Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas |
| Q45717443 | Present status of oncolytic virus studies |
| Q44124151 | Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene |
| Q33388660 | Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors |
| Q37759934 | Regional liver therapy using oncolytic virus to target hepatic colorectal metastases |
| Q40470684 | Replicating vectors for gene therapy of cancer: risks, limitations and prospects |
| Q41335851 | Replicating viruses as selective cancer therapeutics |
| Q33882702 | Replication-selective adenoviruses as oncolytic agents |
| Q40716849 | Replication-selective microbiological agents: fighting cancer with targeted germ warfare |
| Q34293607 | Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer |
| Q35912403 | Replication-selective oncolytic viruses in the treatment of cancer. |
| Q33963944 | Replicative adenoviruses for cancer therapy |
| Q42807227 | Replicative retroviral vectors for cancer gene therapy |
| Q37191007 | Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded |
| Q35043098 | Selectively replicating viral vectors |
| Q40043393 | Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses |
| Q27652596 | Structure of Seneca Valley Virus-001: An Oncolytic Picornavirus Representing a New Genus |
| Q70622318 | Studies on the effect of smallpox vaccine and Freund's adjuvant on the Harding-Passey melanoma in the mouse |
| Q40087770 | Systemic virotherapy for multiple myeloma |
| Q57148977 | The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers |
| Q40026059 | The morphology of tumors of the human gastrointestinal tract in short-term organ culture and the reaction of these tumors to infection with poliovirus |
| Q39160337 | The use of hypoxic cultured mesenchymal stem cell for oncolytic virus therapy |
| Q45871906 | Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses |
| Q35779378 | Tissue-specific promoters for cancer gene therapy |
| Q37028023 | Trial watch: Oncolytic viruses for cancer therapy |
| Q29035807 | Ultrasound-enhanced drug delivery for cancer |
| Q35753524 | Use of suicide genes for cancer gene therapy: study of the different approaches. |
| Q74733273 | VIRUSES in treatment of cancer |
| Q64377567 | Vectorology recapitulates virology--will it capitulate oncology? |
| Q64378232 | Viral oncolysis |
| Q38253646 | Virotherapy in cancer |
| Q40036993 | Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. |
| Q39576352 | Virus Augmentation of The Antigenicity of Tumor Cell |
| Q34311097 | Viruses in cancer treatment |
| Q56343483 | Zika virus as an oncolytic treatment of human neuroblastoma cells requires CD24 |
| Q55471314 | [Oncolytic viral therapy of gliomas: review of the literature] |
Search more.